January 3, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Novocure Ltd (NASDAQ:NVCR) shares over potential securities laws violations by Novocure Ltd and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Novocure Ltd (NASDAQ:NVCR) concerning whether a series of statements by Novocure Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Novocure Ltd reported that its annual Total Revenue rose from $15.49 million in 2014 to $33.09 million in 2015 and that its Net Loss increased from $80.68 million in 2014 to $111.58 million in 2015.

On July 28, 2016, Novocure Ltd reported its second quarter 2016 financial result snad provided a company update. Among other things, Novocure Ltd reported that its new Optune prescriptions fell to 657 in the second quarter from 755 in the first quarter. Asaf Danziger, Chief Executive Officer of Novocure stated that [w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.

On January 3, 2016, NASDAQ:NVCR shares closed at $7.85 per share.